JJP Biologics
- Biotech or pharma, therapeutic R&D
JJP Biologics is an innovative clinical-stage biotechnology company developing the next generation of biologics in autoimmunity and oncology using a personalized medicine approach.
Our two lead assets are: 1) JJP-1212: a first-in-class CD89 antagonizing antibody for IgA-mediated autoimmune & fibrotic diseases currently in Phase I, and 2) JJP-1008: a first-in-class CD270 (HVEM) checkpoint inhibitor for solid tumors & haematological malignancies, currently in preclinical stage.
We are part of the growing Polish biotechnology sector, led by some of the biggest names in the industry and financially backed by the Starak family.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}